April N. Rose
Montreal, QC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications
Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy.
Journal: Cancer treatment reviews
Published: May 01, 2026
mTOR inhibition enhances the antitumor efficacy of pan-RAF-MEK blockade by inhibiting the ATF4-MTHFD2 pathway.
Journal: Cell death & disease
Published: November 10, 2025
Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy.
Journal: medRxiv : the preprint server for health sciences
Published: August 20, 2025
Evaluating the Role of Liquid Biopsy to Detect Pathogenic Homologous Recombination Repair (HRR) Gene Alterations in Metastatic Prostate Cancer.
Journal: Cancers
Published: August 17, 2025
Defining the Prognostic Significance of BRAF V600E in Early-Stage Colon Cancer: A Systematic Review and Meta-Analysis.
Journal: Current oncology (Toronto, Ont.)
Published: July 26, 2025
Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: June 26, 2025
Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers.
Journal: JCO precision oncology
Published: January 27, 2025
The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre.
Journal: Current oncology (Toronto, Ont.)
Published: October 15, 2024
High Ki-67 expression is associated with increased risk of distant recurrence in Oncotype Dx low risk breast cancer.
Journal: Clinical breast cancer
Published: October 08, 2024
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.
Journal: Nature communications
Published: August 22, 2024
A phase 2, single-arm trial evaluating 131 I-PSMA-1095 targeted radioligand therapy for metastatic castration-resistant prostate cancer.
Journal: Nuclear medicine communications
Published: May 10, 2024
How can we integrate the biology of breast cancer cell dormancy into clinical practice?
Journal: Cancer cell
Published: April 10, 2024
Last Updated: 09/26/2026